LUCD — Lucid Diagnostics Balance Sheet
0.000.00%
- $134.85m
- $164.09m
- $4.35m
Annual balance sheet for Lucid Diagnostics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.111 | 53.7 | 22.5 | 18.9 | 22.4 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | 0.2 | 0.017 | 0.045 | 0.045 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1.44 | 57.3 | 24.4 | 22.1 | 25.1 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | — | 0.971 | 3.6 | 2.64 | 3.7 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 2.19 | 59 | 32.5 | 27.3 | 30.7 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 15.7 | 4.26 | 8.43 | 29.4 | 23.5 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 15.7 | 4.26 | 9.46 | 29.6 | 25.3 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -13.5 | 54.7 | 23 | -2.31 | 5.39 |
| Total Liabilities & Shareholders' Equity | 2.19 | 59 | 32.5 | 27.3 | 30.7 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |